Cannabidiol: an overview of some pharmacological aspects

J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. doi: 10.1002/j.1552-4604.2002.tb05998.x.

Abstract

Over the past few years, considerable attention has focused on cannabidiol (CBD), a major nonpsychotropic constituent of cannabis. The authors present a review on the chemistry of CBD and discuss the anticonvulsive, antianxiety, antipsychotic, antinausea, and antirheumatoid arthritic properties of CBD. CBD does not bind to the known cannabinoid receptors, and its mechanism of action is yet unknown. It is possible that, in part at least, its effects are due to its recently discovered inhibition of anandamide uptake and hydrolysis and to its antioxidative effect.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology
  • Anti-Inflammatory Agents / pharmacology
  • Anticonvulsants / pharmacology
  • Antiemetics / pharmacology
  • Antipsychotic Agents / pharmacology
  • Cannabidiol / pharmacology*
  • Humans
  • Hypnotics and Sedatives / pharmacology
  • Nausea / prevention & control

Substances

  • Anti-Anxiety Agents
  • Anti-Inflammatory Agents
  • Anticonvulsants
  • Antiemetics
  • Antipsychotic Agents
  • Hypnotics and Sedatives
  • Cannabidiol